Aarhus University Seal

Lisa Maria Wu

Cognitive impairment following hormone therapy: current opinion of research in breast and prostate cancer patients

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

Cognitive impairment following hormone therapy: current opinion of research in breast and prostate cancer patients. / Wu, Lisa Maria; Amidi, Ali.
In: Current Opinion in Supportive and Palliative Care, Vol. 11, No. 1, 03.2017, p. 38-45.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Wu LM, Amidi A. Cognitive impairment following hormone therapy: current opinion of research in breast and prostate cancer patients. Current Opinion in Supportive and Palliative Care. 2017 Mar;11(1):38-45. doi: 10.1097/SPC.0000000000000251

Author

Wu, Lisa Maria ; Amidi, Ali. / Cognitive impairment following hormone therapy: current opinion of research in breast and prostate cancer patients. In: Current Opinion in Supportive and Palliative Care. 2017 ; Vol. 11, No. 1. pp. 38-45.

Bibtex

@article{41cd99655e784bf6a83eac5d7c64a1e7,
title = "Cognitive impairment following hormone therapy: current opinion of research in breast and prostate cancer patients",
abstract = "Purpose of review Hormone therapy is a common cancer treatment that may be associated with numerous side and late effects, and in recent years, has been linked to changes in cognition. Here, we present the most important recent findings from empirical studies and reviews that have focused on the effects of hormone therapy on cognitive functioning in breast and prostate cancer populations, underline some general shortcomings, and propose directions for future research. Recent findings Recent research indicates that cognitive impairment may occur in breast and prostate cancer patients following onset of hormone therapy. However, because of methodological shortcomings and heterogeneity of current research, conclusions regarding the effects of hormone therapy on cognitive functions remain tentative. Summary The review highlights the general findings while also describing the many methodological shortcomings that need to be addressed in future research. It is clear that larger scale neuropsychological studies that also evaluate the impact of impairments on daily life functioning will improve our understanding of the effects of hormone therapy on cognition and inform the development of appropriate interventions.",
keywords = "androgen deprivation therapy, cancer, cognitive impairment, endocrine therapy, hormone therapy",
author = "Wu, {Lisa Maria} and Ali Amidi",
year = "2017",
month = mar,
doi = "10.1097/SPC.0000000000000251",
language = "English",
volume = "11",
pages = "38--45",
journal = "Current Opinion in Supportive and Palliative Care",
issn = "1751-4258",
publisher = "Lippincott Williams & Wilkins, Ltd.",
number = "1",

}

RIS

TY - JOUR

T1 - Cognitive impairment following hormone therapy: current opinion of research in breast and prostate cancer patients

AU - Wu, Lisa Maria

AU - Amidi, Ali

PY - 2017/3

Y1 - 2017/3

N2 - Purpose of review Hormone therapy is a common cancer treatment that may be associated with numerous side and late effects, and in recent years, has been linked to changes in cognition. Here, we present the most important recent findings from empirical studies and reviews that have focused on the effects of hormone therapy on cognitive functioning in breast and prostate cancer populations, underline some general shortcomings, and propose directions for future research. Recent findings Recent research indicates that cognitive impairment may occur in breast and prostate cancer patients following onset of hormone therapy. However, because of methodological shortcomings and heterogeneity of current research, conclusions regarding the effects of hormone therapy on cognitive functions remain tentative. Summary The review highlights the general findings while also describing the many methodological shortcomings that need to be addressed in future research. It is clear that larger scale neuropsychological studies that also evaluate the impact of impairments on daily life functioning will improve our understanding of the effects of hormone therapy on cognition and inform the development of appropriate interventions.

AB - Purpose of review Hormone therapy is a common cancer treatment that may be associated with numerous side and late effects, and in recent years, has been linked to changes in cognition. Here, we present the most important recent findings from empirical studies and reviews that have focused on the effects of hormone therapy on cognitive functioning in breast and prostate cancer populations, underline some general shortcomings, and propose directions for future research. Recent findings Recent research indicates that cognitive impairment may occur in breast and prostate cancer patients following onset of hormone therapy. However, because of methodological shortcomings and heterogeneity of current research, conclusions regarding the effects of hormone therapy on cognitive functions remain tentative. Summary The review highlights the general findings while also describing the many methodological shortcomings that need to be addressed in future research. It is clear that larger scale neuropsychological studies that also evaluate the impact of impairments on daily life functioning will improve our understanding of the effects of hormone therapy on cognition and inform the development of appropriate interventions.

KW - androgen deprivation therapy

KW - cancer

KW - cognitive impairment

KW - endocrine therapy

KW - hormone therapy

UR - http://www.scopus.com/inward/record.url?scp=85013175421&partnerID=8YFLogxK

U2 - 10.1097/SPC.0000000000000251

DO - 10.1097/SPC.0000000000000251

M3 - Journal article

C2 - 27926544

VL - 11

SP - 38

EP - 45

JO - Current Opinion in Supportive and Palliative Care

JF - Current Opinion in Supportive and Palliative Care

SN - 1751-4258

IS - 1

ER -